Intranasal ipratropium bromide for the common cold.

摘要: Background: The common cold is one of the most illnesses in humans and constitutes an economic burden both terms productivity expenditure for treatment. There no proven cure symptomatic relief mainstay use intranasal ipratropium bromide (IB) has been addressed several studies might prove effective treatment cold. Objectives: To determine effect IB versus placebo or on severity rhinorrhoea nasal congestion children adults with Subjective overall improvement was another primary outcome side effects were reported as a secondary outcome. Search strategy: We searched Cochrane Central Register Controlled Trials (CENTRAL 2011, Issue 1) which contains Acute Respiratory Infections Group's Specialised Register, MEDLINE (1950 to January week 4, 2011), in-process other non-indexed citations (February EMBASE (1974 February AMED (1985 Biosis 2011) LILACS 2011). Selection criteria: Randomised controlled trials (RCTs) comparing Data collection analysis: Two review authors independently extracted data assessed trial quality. used standardised form extract relevant we contacted additional information. Main results: Seven total 2144 participants included. Four (1959 participants) subjective change rhinorrhoea. All consistent reporting statistically significant changes favour IB. Nasal four found have between two groups. positive response group global assessment improvement. Side more frequent group, odds ratio (OR) 2.09 (95% confidence interval (CI) 1.40 3.11). Commonly encountered included dryness, blood tinged mucus epistaxis. Authors' conclusions: For people cold, existing evidence, some limitations, suggests that likely be ameliorating had its associated compared although these appeared well-tolerated self-limiting. need larger, high-quality effectiveness relieving symptoms.